×
Dogwood Therapeutics EBITDA 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Dogwood Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Dogwood Therapeutics EBITDA 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Dogwood Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141B
Bristol Myers Squibb (BMY)
$113.2B
Gilead Sciences (GILD)
$112B
Vertex Pharmaceuticals (VRTX)
$105.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$76.6B
GSK (GSK)
$68.6B
Argenex SE (ARGX)
$39.6B
Alnylam Pharmaceuticals (ALNY)
$30.7B
BioNTech SE (BNTX)
$29.5B
Biogen (BIIB)
$21.7B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$17.3B
Moderna (MRNA)
$16.3B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.6B
BioMarin Pharmaceutical (BMRN)
$12.8B
Sarepta Therapeutics (SRPT)
$11.9B
Insmed (INSM)
$11.7B
Bio-Techne Corp (TECH)
$11.6B
Exact Sciences (EXAS)
$10.5B
Exelixis (EXEL)
$10.3B
QIAGEN (QGEN)
$10.2B
Vaxcyte (PCVX)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Intra-Cellular Therapies (ITCI)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$8.7B
Ascendis Pharma (ASND)
$7.8B